12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALN-TTR02: Interim Phase II data

Interim data from 19 evaluable patients with TTR-mediated amyloidosis in an open-label, dose-escalation, international Phase II trial showed that multiple doses of IV ALN-TTR02 led to rapid, dose-dependent and significant knockdown of serum TTR protein levels of up to 92.8%. Specifically, maximum percent reductions in TTR were 37.8% following the first dose of 0.01 mg/kg ALN-TTR02 every 4 weeks and 34.4% following the second dose; 58% following the first dose of 0.05 mg/kg ALN-TTR02 every 4 weeks and 58.5% following the second dose; 81.7% following the first dose of 0.15 mg/kg ALN-TTR02 every 4 weeks and 86% following the second dose; 87.5% following the first dose of 0.3 mg/kg ALN-TTR02 every 4 weeks and 90.8% following the second dose;...

Read the full 575 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >